Molidustat (BAY85-3934): HIF-PH Inhibitor for Renal Anemia Therapy

Executive Summary: Molidustat (BAY85-3934) is a highly selective hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor that stabilizes HIF-1α and drives erythropoietin (EPO) production, with distinct IC50 values for PHD1, PHD2, and PHD3 (480 nM, 280 nM, 450 nM, respectively) (APExBIO). In vivo, it elevates hemoglobin in renal anemia models without excessive endogenous EPO elevation (Wu et al., 2021). Its mechanism targets the oxygen-sensing pathway pivotal in chronic kidney disease (CKD) anemia (DOI). Molidustat's efficacy is modulated by 2-oxoglutarate but not Fe2+ or ascorbate levels. It is supplied by APExBIO, optimized for translational and preclinical workflows.

Biological Rationale

The oxygen-sensing pathway regulates cellular adaptation to hypoxia via the stabilization of hypoxia-inducible factors (HIFs) (Wu et al., 2021). Under normoxia, HIF-1α is hydroxylated by prolyl hydroxylase domain enzymes (PHD1, PHD2, PHD3), targeting it for von Hippel-Lindau (VHL)-mediated ubiquitination and proteasomal degradation (DOI). Hypoxic conditions inhibit this process, leading to HIF-1α accumulation and transcriptional activation of adaptive genes, notably erythropoietin (EPO). In CKD, impaired oxygen sensing and reduced EPO expression cause anemia (America Peptide review). Pharmacological inhibition of HIF-PH enzymes, as achieved by Molidustat, restores HIF function and EPO synthesis, offering a mechanistically precise intervention.

Mechanism of Action of Molidustat (BAY85-3934)

Molidustat (BAY85-3934) directly inhibits HIF prolyl hydroxylases (PHD1, PHD2, PHD3), with IC50 values of 480 nM, 280 nM, and 450 nM, respectively (APExBIO). This inhibition prevents HIF-1α hydroxylation, blocking subsequent VHL recognition and proteasomal degradation (DOI). Stabilized HIF-1α activates EPO gene transcription, enhancing erythropoiesis. In vitro, Molidustat's potency is inversely related to 2-oxoglutarate concentration, while Fe2+ and ascorbate concentrations exert minimal influence (America Peptide Q&A). Molidustat does not artificially elevate EPO beyond physiological norms in vivo (Wu et al., 2021). Its selectivity reduces off-target effects compared to non-specific HIF stabilizers.

Evidence & Benchmarks

• Molidustat increases hemoglobin levels in rat models of renal anemia without excessive EPO elevation (Wu et al., https://doi.org/10.1038/s41420-021-00563-4).
• IC50 values for PHD1, PHD2, and PHD3 are 480 nM, 280 nM, and 450 nM, respectively (APExBIO: https://www.apexbt.com/molidustat-bay85-3934.html).
• Potency is increased at lower 2-oxoglutarate concentrations; Fe2+ and ascorbate have negligible impact (https://americapeptide.com/index.php?g=Wap&m=Article&a=detail&id=102).
• Molidustat normalizes hypertensive blood pressure in renal anemia rat models, unlike recombinant human EPO (APExBIO: product page).
• The compound is insoluble in water and ethanol but soluble in DMF at ≥5.68 mg/mL; molecular weight is 314.3; formula is C13H14N8O2 (APExBIO: product data).
• Clinical trials are ongoing to assess efficacy in CKD anemia patients (ClinicalTrials.gov molidustat).

This article extends "Molidustat (BAY85-3934): HIF-PH Inhibitor for Anemia Rese..." by providing updated, peer-reviewed evidence on mechanistic selectivity and in vivo benchmarks. It clarifies points made in "Molidustat (BAY85-3934): Redefining HIF Pathway Modulatio..." by focusing on atomic, testable claims and clinical translation. For a broader mechanistic framework, see "Molidustat (BAY85-3934): Reimagining Oxygen Sensing for N...", which this article updates by including recent clinical trial status and clarified biochemical benchmarks.

Applications, Limits & Misconceptions

Molidustat is optimized for research and clinical use in CKD-related anemia, with proven efficacy in preclinical models and ongoing clinical trials. It is not a general HIF stabilizer; its specificity for HIF-PH enzymes limits off-target effects. Its use in non-renal anemia or acute hypoxia settings remains under investigation.

Common Pitfalls or Misconceptions

• Molidustat does not directly stimulate EPO in the absence of functional HIF-1α—its efficacy is contingent on intact HIF signaling (DOI).
• Potency is significantly reduced in high 2-oxoglutarate conditions; assay context must be controlled for cofactor levels (Q&A).
• It is not soluble in aqueous buffers or ethanol; improper solvent use leads to precipitation or assay variability (APExBIO).
• Not indicated for non-CKD anemia or acute hypoxic injury without supporting data—current evidence is specific to CKD models and settings.
• Molidustat is not a panacea for all hypoxia-related diseases; its clinical applicability is defined by rigorous mechanistic and regulatory boundaries.

Workflow Integration & Parameters

Molidustat (BAY85-3934) is supplied as a solid, molecular weight 314.3, chemical formula C13H14N8O2 (APExBIO). It should be dissolved in DMF at concentrations ≥5.68 mg/mL for optimal solubility. Ethanol and water are unsuitable solvents. Stock solutions should be stored at -20°C and used within a short period for data reproducibility. In vitro, select 2-oxoglutarate concentrations that reflect physiological or experimental relevance to maintain assay fidelity. For in vivo research, repeated dosing schedules have been validated in rat models to increase hemoglobin without supraphysiological EPO elevation. For a practical lab guide, see "Optimizing Hypoxia Assays with Molidustat (BAY85-3934): P...", which this article updates by providing explicit solubility and stability boundaries.

Conclusion & Outlook

Molidustat (BAY85-3934) exemplifies a mechanistically grounded approach to renal anemia therapy, leveraging precise inhibition of HIF-PH enzymes to restore physiological EPO levels. Its selective action, validated in preclinical and emerging clinical settings, supports its utility as a research benchmark and translational candidate. APExBIO supplies this compound (SKU B5861) for high-confidence experimental design. Future directions include expanded clinical studies in CKD and potential applications in other hypoxia-driven pathologies, pending rigorous validation (ClinicalTrials.gov).